References
- Chams-Davatchi C, Valikhani M, Daneshpazhooh M, et al. Pemphigus: analysis of 1209 cases. Int J Dermatol. 2005;44:470–6.
- Braunstein I, Werth V. Treatment of dermatologic connective tissue disease and autoimmune blistering disorders in pregnancy. Dermatol Ther. 2013;26:354–63.
- El Tal AK, Posner MR, Spigelman Z, et al. Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris. J Am Acad Dermatol. 2006;55:449–59.
- Ahmed AR, Spigelman Z, Cavacini LA, et al. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006;355:1772–9.
- Cianchini G, Corona R, Frezzolini A, et al. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature. Arch Dermatol. 2007;143:1033–8.
- Klink DT, van Elburg RM, Schruers MW, et al. Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin Dev Immunology. 2008;2008:271363.
- Herbst A, Bystryn JC. Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol. 2000;42:422–7.
- Ton E, Tekstra J, Hellmann PM, et al. Safety of rituximab therapy during twins' pregnancy. Rheumatology (Oxford). 2011;50:806–8.